Atlas Trials

Effect of Novel Glucagon Receptor Antagonist REMD-477 on Glucose and Adipocyte Metabolism in T2DM

Clinical trial NCT05093517 · COMPLETED

Trial details

NCT number
NCT05093517
Sponsor
The University of Texas Health Science Center at San Antonio
Status
COMPLETED
Phase
Early Phase 1
Study type
INTERVENTIONAL
Type 2 DiabetesGlucose Tolerance ImpairedInsulin Sensitivity
Start date
2021-11-10
Primary completion
2022-03-16
Enrollment
4

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.